Literature DB >> 28677682

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

M Robin, R Porcher, W Zinke-Cerwenka, A van Biezen, L Volin, G Mufti, C Craddock, J Finke, C Richard, J Passweg, A Peniket, J Maertens, G Sucak, T Gedde-Dahl, A Vitek, A Nagler, D Blaise, D Beelen, N Maillard, R Schwerdtfeger, T de Witte, N Kroger.   

Abstract

This corrects the article DOI: 10.1038/bmt.2016.266.

Entities:  

Year:  2017        PMID： 28677682     DOI： 10.1038/bmt.2017.86

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Lower risk but high risk.

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.

Authors:  Marie Anne Hospital; Norbert Vey
Journal:  Curr Oncol Rep       Date:  2020-01-23       Impact factor: 5.075

Review 3.  BMT for Myelodysplastic Syndrome: When and Where and How.

Authors:  Akriti G Jain; Hany Elmariah
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

Review 4.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.